Skip to main content

Sound Pharmaceuticals (SPI) has filed an investigative new drug (IND) application with the United States Food and Drug Administration (FDA) for their investigative oral agent SPI-3005 (ebselen). The IND is for use of SPI-3005 for the prevention of hearing loss (ototoxicity) induced by chemotherapy.

SPI-3005 has been designed to attenuate platinum or taxane-based chemotherapy ototoxicity without interfering with their effectiveness.

SPI-3005 will be tested in clinical trials including patients with advanced lung and head and neck cancer patients being treated with platinum-based chemotherapy.

Scroll to Continue

Recommended Articles

Image placeholder title

Sarclisa (isatuximab) – Anti CD38 Targeted Therapy for Myeloma

Sarclisa precision cancer medicine improves survival in advanced Multiple Myeloma - leads to FDA approval